Open AccessEmerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Author(s) -
Élia Cipriano,
Anabela Mesquita
Publication year - 2021
Publication title -
breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.741
H-Index - 23
ISSN - 1178-2234
DOI - 10.1177/11782234211002491
Subject(s) - medicine , olaparib , triple negative breast cancer , atezolizumab , oncology , carboplatin , metastatic breast cancer , parp inhibitor , chemotherapy , gemcitabine , breast cancer , pembrolizumab , targeted therapy , lapatinib , eribulin , cancer , immunotherapy , trastuzumab , poly adp ribose polymerase , cisplatin , biology , biochemistry , polymerase , gene
Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. Treatment of these patients is highly based on systemic chemotherapy. Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymerase inhibitors in patients with germline BRCA1/2 mutations (olaparib and talazoparib), immune checkpoint inhibitors in association with chemotherapy if programmed death-ligand 1 positive (atezolizumab plus nabpaclitaxel and pembrolizumab plus chemotherapy [nabpaclitaxel, paclitaxel, and carboplatin plus gemcitabine]), and an antibody-drug conjugate sacituzumab-govitecan in heavily pretreated patients (at least 2 previous lines for the metastatic setting). Combinations using these and other targeted treatment options are under investigation in early and late clinical trials, and we will probably have some practice-changing results in the new future. Other targeted drugs explored in phase II and phase III clinical trials are PI3K/AKT pathway inhibitors and androgen receptor antagonists in patients with alterations in these signaling pathways. The definition of molecular subtypes has been essential for the development of these treatment strategies. Soon, the treatment of metastatic TNBC could be based on personalized medicine using molecular testing for targeted drugs instead of only systemic chemotherapy. The authors present a review of emerging treatment options in metastatic TNBC, focusing on targeted drugs, including the recent data published in 2020.